Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abacavir/dolutegravir/lamivudine - ViiV Healthcare

Drug Profile

Abacavir/dolutegravir/lamivudine - ViiV Healthcare

Alternative Names: '572-Trii; 572 Trii; Abacavir/GSK-1349572/lamivudine; Dolutegravir-Trii; Dolutegravir/abacavir/lamivudine; DTG/ABC/3TC; DTG/ABC/3TC FDC; GSK-1349572/abacavir/lamivudine; Lamivudine/abacavir/GSK-1349572; Triumeq

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Shionogi ViiV Healthcare LLC
  • Developer GlaxoSmithKline; Shionogi ViiV Healthcare LLC; ViiV Healthcare
  • Class Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Oxazines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 22 Sep 2021 Biomarkers information updated
  • 23 Jul 2021 ViiV Healthcare completes a phase I trial in healthy volunteers in USA (PO) (NCT04827134)
  • 07 May 2021 ViiV Healthcare initiates a phase I trial in healthy volunteers in USA (PO) (NCT04827134)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top